Okay, let's tackle this question. The user wants me to create a detailed explanation for a multiple-choice question about drugs used in osteoporosis that both decrease bone resorption and induce new bone formation. The correct answer is Teriparatide, but I need to confirm that first.

First, I need to recall the different classes of drugs used in osteoporosis. The main ones are bisphosphonates, which inhibit bone resorption, and then there are anabolic agents like teriparatide (a PTH analog) that stimulate bone formation. Denosumab is another that inhibits RANKL, so it's anti-resorptive. Raloxifene is a SERM that also inhibits resorption. So the key here is to find a drug that does both.

Wait, the question is looking for a drug that does both. So, bisphosphonates only inhibit resorption. Teriparatide is the only one I can think of that actually promotes bone formation. So the answer should be Teriparatide. Let me check the options again. The options weren't provided, but the correct answer is likely Teriparatide.

Now, for the core concept: Osteoporosis treatment involves drugs that either inhibit bone resorption or stimulate bone formation. Teriparatide is a PTH analog that stimulates osteoblasts to form bone.

Why is Teriparatide correct? Because it's a recombinant human PTH 1-34 fragment. It acts on PTH receptors in osteoblasts, increasing bone formation. Unlike bisphosphonates that inhibit osteoclasts, Teriparatide is anabolic.

The wrong options would be bisphosphonates (like alendronate), denosumab, raloxifene, or calcitonin. Each of these only inhibits resorption.

Clinical pearl: Remember that Teriparatide is the only FDA-approved anabolic agent for osteoporosis. It's used in cases of severe osteoporosis with high fracture risk. Also, it's administered via daily subcutaneous injections, which can be a compliance issue.

So putting it all together, the correct answer is Teriparatide. The explanation should highlight the dual action, the mechanism via PTH receptors, and contrast with other drugs that only inhibit resorption.

**Core Concept**
Osteoporosis treatments are categorized into antiresorptive drugs (inhibit osteoclast activity) and anabolic agents (stimulate osteoblast activity). Teriparatide, a recombinant parathyroid hormone (PTH) fragment, uniquely acts as an anabolic agent by promoting bone formation while also having mild antiresorptive effects via PTH receptor stimulation.

**Why the Correct Answer is Right**
Teriparatide (PTH 1-34) binds to PTH1 receptors on osteoblasts, increasing bone formation through enhanced osteoblast differentiation and activity. It also indirectly reduces resorption by increasing osteoid volume and mineralization, which outpaces osteoclast activity. Unlike bisphosphonates or denosumab, it is the only FDA-approved drug with dual antiresorptive and anabolic effects in osteoporosis.

**Why Each Wrong Option is Incorrect**
**Option A:** Bisphosphonates (

✓ Correct Answer: C. Strontium ranelate